| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action activators, inhibitors | 
| Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseNDA/BLA | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC25H29ClO6 | 
| InChIKeyWDBIPGHUEJEKTC-CGTLGCROSA-N | 
| CAS Registry1800115-22-3 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | NDA/BLA | China  | 17 May 2022 | 





